December 9, 2015 Off

Bayer’s Xarelto in deep vein thrombosis treatment confirm low rates of major bleeding seen in pivotal trial

By Dino Mustafić

The non-interventional XALIA study in patients with deep vein thrombosis (DVT) and a study in patients with cancer-associated thrombosis (CAT) – both showing low rates of major bleeding and recurrent venous thromboembolism (VTE) with Xarelto (rivaroxaban). Results from the two studies were presented at the 2015 ASH Annual Meeting, and XALIA findings were also simultaneously published in the Lancet Haematology.